S. Hess

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study

A. Camm, P. Kirchhof, P. Amarenco, 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy

A. Camm, P. Kirchhof, A. Camm, 2016, Clinical cardiology.

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study

A. Camm, P. Kirchhof, P. Amarenco, 2018, European heart journal. Cardiovascular pharmacotherapy.

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

A. Camm, P. Kirchhof, P. Amarenco, 2015, European heart journal.

Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients

S. Berkowitz, R. Friedman, M. Homering, 2013, Clinical orthopaedics and related research.

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

S. Hohnloser, F. Marchlinski, R. Cappato, 2015, European heart journal.

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

A. Camm, P. Kirchhof, G. Lip, 2016, European heart journal.

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban

A. Camm, P. Kirchhof, P. Amarenco, 2020, Journal of the American Heart Association.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS

A. Camm, P. Kirchhof, P. Amarenco, 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Global Prospective Safety Analysis of Rivaroxaban.

P. Kirchhof, A. Camm, P. Amarenco, 2018, Journal of the American College of Cardiology.

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

A. Camm, P. Kirchhof, J. Camm, 2014, Vascular health and risk management.

Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation

S. Hohnloser, F. Marchlinski, R. Cappato, 2014, Journal of Interventional Cardiac Electrophysiology.

University of Birmingham XANTUS : rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

P. Kirchhof, A. Camm, P. Amarenco, 2014 .

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

A. Camm, P. Kirchhof, H. Heidbuchel, 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS

A. Turpie, M. Bach, Marc Lambelet, 2024, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.